SCHEMBL4871083

SCHEMBL4871083

COC(=O)c1cc(-c2ccncc2)cc2c1OC(c1ccccc1)(c1ccccc1)O2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
NR4A2 P43354 3/20 0.41
AXL P30530 2/20 0.41
IKBKB O14920 2/20 0.41
CYP46A1 Q9Y6A2 1/20 0.41
PKN1 Q16512 1/20 0.39
PKN2 Q16513 1/20 0.39
KDM4E B2RXH2 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
GAA P10253 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867176 0.87 NR4A2 (0.41) ALDH1A1NR4A2AXLKDM4EMEN1
SCHEMBL4861896 0.87 DHODH (0.43) ALDH1A1IKBKBKDM4EGAAHPGD
SCHEMBL4868951 0.86 SLC6A4 (0.46) ALDH1A1NR4A2KDM4EMEN1KMT2A
SCHEMBL8285546 0.84 KMT2A (0.40) ALDH1A1NR4A2CYP46A1KDM4EMEN1
SCHEMBL4870705 0.82 TACR3 (0.38) ALDH1A1NR4A2AXLKDM4EMEN1
SCHEMBL4868406 0.80 KDM4E (0.42) ALDH1A1NR4A2KDM4EMEN1KMT2A
SCHEMBL14588690 0.80 CNR1 (0.38) ALDH1A1NR4A2KDM4EMAPTHPGD
SCHEMBL4868416 0.80 ALDH1A1 (0.41) ALDH1A1NR4A2KDM4EMEN1KMT2A
SCHEMBL4863666 0.78 ALDH1A1 (0.46) ALDH1A1KDM4EMEN1KMT2AGAA
SCHEMBL4863014 0.78 KDM4E (0.37) ALDH1A1NR4A2KDM4ETDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-A2 COMT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-06 EP disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition F. HOFFMANN-LA ROCHE AG (CH) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition COMT, MAOB, TPH1 ALDH1A1 46/4885NR4A2 2527/4885AXL 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.